Moussa, Charbel E-H

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Autophagy

Autophagy in Disease and TherapyCalcium signaling and nucleotide metabolism

Cited by 5,894

Guidelines for the use and interpretation of assays for monitoring autophagy

Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J. A., et al. (2012) · Autophagy

Autophagy in Disease and TherapyCalcium signaling and nucleotide metabolism

Cited by 3,996

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 265

Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury

Loane, D. J., Pocivavsek, A., Moussa, C. E.-H., Thompson, R., Matsuoka, Y., Faden, A. I., Rebeck, G. W., & Burns, M. P. (2009) · Nature Medicine

Traumatic Brain Injury and Neurovascular DisturbancesAlzheimer's disease research and treatments

Cited by 246

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial

Pagan, F. L., Hebron, M. L., Wilmarth, B., Torres-Yaghi, Y., Lawler, A., Mundel, E. E., Yusuf, N., Starr, N. J., Anjum, M., Arellano, J., et al. (2020) · JAMA Neurology

Parkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatments

Cited by 185

Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance

Lonskaya, I., Hebron, M. L., Desforges, N. M., Schachter, J. B., & Moussa, C. E.-H. (2014) · Journal of Molecular Medicine

Alzheimer's disease research and treatmentsAutophagy in Disease and Therapy

Cited by 152

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer’s Disease

Turner, R. S., Hebron, M. L., Lawler, A., Mundel, E. E., Yusuf, N., Starr, J. N., Anjum, M., Pagan, F., Torres‐Yaghi, Y., Shi, W., et al. (2020) · Annals of Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 126

APOE genotype affects the pre‐synaptic compartment of glutamatergic nerve terminals

Dumanis, S. B., DiBattista, A. M., Miessau, M., Moussa, C. E. H., & Rebeck, G. W. (2013) · Journal of Neurochemistry

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 55

Human APOE genotype affects intraneuronal A 1-42 accumulation in a lentiviral gene transfer model

Zhao, W., Dumanis, S. B., Tamboli, I. Y., Rodriguez, G. A., Jo LaDu, M., Moussa, C. E. H., & William Rebeck, G. (2014) · Human Molecular Genetics

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 32

Parkin is dispensable for mitochondrial function, but its ubiquitin ligase activity is critical for macroautophagy and neurotransmitters: therapeutic potential beyond Parkinson's disease

Moussa, C. E.-H. (2015) · Neurodegenerative Diseases

Parkinson's Disease Mechanisms and TreatmentsAutophagy in Disease and Therapy

Cited by 13